Evidence map›Paper›PMID 28423002›Full record

ArticlePloS one2017

Human SR-BII mediates SAA uptake and contributes to SAA pro-inflammatory signaling in vitro and in vivo.

Irina N Baranova, Ana C P Souza, Alexander V Bocharov, Tatyana G Vishnyakova, Xuzhen Hu, Boris L Vaisman, Marcelo J Amar, Zhigang Chen, Alan T Remaley, Amy P Patterson and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Serum Amyloid A-Mediated Inflammasome Activation of Microglial Cells in Cerebral Ischemia.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019
    Article
  12. Kidney as modulator and target of "good/bad" HDL.Pediatric nephrology (Berlin, Germany) · 2019
    Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Irina N BaranovaDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, United States of America.ORCID http://orcid.org/0000-0003-4250-1340
Ana C P SouzaRenal Diagnostics and Therapeutics Unit, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Alexander V BocharovDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, United States of America.
Tatyana G VishnyakovaDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, United States of America.
Xuzhen HuRenal Diagnostics and Therapeutics Unit, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Boris L VaismanNational Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Marcelo J AmarNational Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Zhigang ChenDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, United States of America.
Alan T RemaleyNational Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Amy P PattersonDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, United States of America.
Peter S T YuenRenal Diagnostics and Therapeutics Unit, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Robert A StarRenal Diagnostics and Therapeutics Unit, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Thomas L EggermanDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, United States of America.
National Institutes of Health · USNational Institutes of Health Clinical Center · US

Funding

Inhibition Of Renal InjuryZIADK043403 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI STAR, ROBERT A · 2009 to 2025
$15.5M
Use Of Animal Models To Study Lipid Genes That Modulate AtherosclerosisZIAHL002058 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI REMALEY, ALAN THOMAS · 2009 to 2019
$14.3M
6 · The paper itself

Abstract

Serum amyloid A (SAA) is an acute phase protein with cytokine-like and chemotactic properties, that is markedly up-regulated during various inflammatory conditions. Several receptors, including FPRL-1, TLR2, TLR4, RAGE, class B scavenger receptors, SR-BI and CD36, have been identified as SAA receptors. This study provides new evidence that SR-BII, splice variant of SR-BI, could function as an SAA receptor mediating its uptake and pro-inflammatory signaling. The uptake of Alexa Fluor488 SAA was markedly (~3 fold) increased in hSR-BII-expressing HeLa cells when compared with mock-transfected cells. The levels of SAA-induced interleukin-8 secretion by hSR-BII-expressing HEK293 cells were also significantly (~3-3.5 fold) higher than those detected in control cells. Moderately enhanced levels of phosphorylation of all three mitogen-activated protein kinases, ERK1/2, and p38 and JNK, were observed in hSR-BII-expressing cells following SAA stimulation when compared with control wild type cells. Transgenic mice with pLiv-11-directed liver/kidney overexpression of hSR-BI or hSR-BII were used to assess the in vivo role of each receptor in SAA-induced pro-inflammatory response in these organs. Six hours after intraperitoneal SAA injection both groups of transgenic mice demonstrated markedly higher (~2-5-fold) expression levels of inflammatory mediators in the liver and kidney compared to wild type mice. Histological examinations of hepatic and renal tissue from SAA-treated mice revealed moderate level of damage in the liver of both transgenic but not in the wild type mice. Activities of plasma transaminases, biomarkers of liver injury, were also moderately higher in hSR-B transgenic mice when compared to wild type mice. Our findings identify hSR-BII as a functional SAA receptor that mediates SAA uptake and contributes to its pro-inflammatory signaling via the MAPKs-mediated signaling pathways.

Indexed as

AnimalsBiological TransportFluorescent DyesFluorobenzenesGene Expression RegulationHEK293 CellsHeLa CellsHumansInflammationKidneyLiverLysosomal Membrane ProteinsMAP Kinase Kinase 4MiceMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Fluorescent DyesFluorobenzenesLysosomal Membrane ProteinsMapk1 protein, mouseMAP Kinase Kinase 4Mitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3p38 Mitogen-Activated Protein KinasesReceptors, ScavengerSCARB2 protein, humanSerum Amyloid A Protein

Identifiers

PMID28423002
PMCPMC5396919
OpenAlexW2605927368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.